300142 Stock Overview
Researches, develops, produces, and markets vaccines in China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Walvax Biotechnology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥14.51 |
| 52 Week High | CN¥25.45 |
| 52 Week Low | CN¥9.78 |
| Beta | 0.72 |
| 11 Month Change | -1.43% |
| 3 Month Change | 23.07% |
| 1 Year Change | -39.87% |
| 33 Year Change | -70.70% |
| 5 Year Change | -54.85% |
| Change since IPO | 29.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300142 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -8.3% | -4.1% | -1.2% |
| 1Y | -39.9% | -16.9% | 3.1% |
Return vs Industry: 300142 underperformed the CN Biotechs industry which returned -16.9% over the past year.
Return vs Market: 300142 underperformed the CN Market which returned 3.1% over the past year.
Price Volatility
| 300142 volatility | |
|---|---|
| 300142 Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in CN Market | 12.0% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 300142's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 300142's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 2,388 | Runsheng Jiang | www.walvax.com |
Walvax Biotechnology Co., Ltd., researches, develops, produces, and markets vaccines in China. The company offers SARS-CoV-2 mRNA vaccine, an immunization to prevent COVID-19 to individuals 18 years of age and older; 13-valent pneumococcal polysaccharide conjugate vaccine, an invasive diseases caused by streptococcus pneumoniae for use in infants and children 6 weeks through 5 years of age; and recombinant human papillomavirus bivalent vaccine, for the prevention of cervical cancers and precancerous lesions caused by human; 23-valent pneumococcal polysaccharide vaccine, for individuals age 2 years of pneumococcal diseases; ACYW135 meningococcal polysaccharide vaccine, for the prevention of invasive meningococcal diseases; Group A and C meningococcal polysaccharide vaccine, for in adults and children over the age of 2 years and adults to prevent disease caused by the bacterium neisseria meningitidis; Group A and Group C meningococcal conjugate vaccine, for the prevention of invasive meningococcal diseases caused by Neisseria meningitidis serogroups A and C for children 3 months through 5 years of age. It also provides haemophilus influenzae type b conjugate vaccine, for the prevention of invasive infections for children 2 months through 5 years of age; diphtheria, tetanus, and acellular pertussis combined vaccine, for diphtheria and tetanus for infants and children 3 months through 6 years of age.
Walvax Biotechnology Co., Ltd. Fundamentals Summary
| 300142 fundamental statistics | |
|---|---|
| Market cap | CN¥23.21b |
| Earnings (TTM) | CN¥122.37m |
| Revenue (TTM) | CN¥3.10b |
189.6x
P/E Ratio7.5x
P/S RatioIs 300142 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300142 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.10b |
| Cost of Revenue | CN¥740.12m |
| Gross Profit | CN¥2.36b |
| Other Expenses | CN¥2.23b |
| Earnings | CN¥122.37m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.077 |
| Gross Margin | 76.10% |
| Net Profit Margin | 3.95% |
| Debt/Equity Ratio | 6.1% |
How did 300142 perform over the long term?
See historical performance and comparison